Aromatase inhibitors in breast cancer.

By I. Smith, Mitchell Dowsett. New England Journal of Medicine, 2003

1,005 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/71f2637efd028474ef6ec212f0c2215e37135a69

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Mitchell Dowsett
2. J. Lamb
3. S. Shak
4. Frederick L. Baehner

In Genetics

1. Mitchell Dowsett
2. J. Lamb

In Oncology

1. N. Hynes
2. J. Lamb
3. A. Kinghorn
4. Marcy J. Balunas
5. J. Baselga

Citations in the corpus

• ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “Consequently, several aromatase inhibitors that reduce oestrogen biosynthesis, such as letrozole and anastrozole, have also been developed as part of a therapeutic strategy aimed at expanding on the clinical success of anti-oestrogens (reviewed in Ref”
• Drug discovery from medicinal plants. (2005, background): “The inhibition of aromatase in post-menopausal women has been found to reduce the recurrence of breast cancer (Johnston and Dowsett, 2003; Smith and Dowsett, 2003).”
• The role of estrogens in control of energy balance and glucose homeostasis. (2013, background): “Because AIs inhibit aromatase, postmenopausal women taking AIs experience a further decrease in circulating estrogens and a theoretical increase in androgens (357).”
• Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. (2010, background): “Large randomized trials have established the safety and efficacy of aromatase inhibitors (AIs) in patients with hormone receptor–positive breast cancer, and AIs are widely used in clinical practice.(6) The performance of the RS has not been evaluated in patients treated with an AI.”
• The Connectivity Map: a new tool for biomedical research (2007, background): “Although they ultimately affect breast epithelial cells, they do so by blocking oestrogen synthesis in the strom”
• Risk Factors and Preventions of Breast Cancer (2017, background): “AIs reduce the plasma levels of estrogens by inhibiting aromatase, an enzyme that catalyzes the biosynthesis of estrogen from androgen [103].”